-+ 0.00%
-+ 0.00%
-+ 0.00%

ImmunityBio launches ANKTIVA in Saudi Arabia, expanding Middle East presence

PUBT·04/21/2026 11:30:34
Listen to the news
ImmunityBio launches ANKTIVA in Saudi Arabia, expanding Middle East presence
  • ImmunityBio launched commercial availability of ANKTIVA in Saudi Arabia, marking an expansion into MENA within two months of its regional partnership rollout.
  • Distribution runs through partnerships with Biopharma, Cigalah Healthcare.
  • Initial patients identified across approved uses in bladder cancer, metastatic non-small cell lung cancer.
  • Saudi Food and Drug Authority authorized ANKTIVA for bladder cancer in January 2026, cleared a combination use in metastatic NSCLC under accelerated approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260421405182) on April 21, 2026, and is solely responsible for the information contained therein.